TransMedics (TMDX) Current Deferred Revenue (2018 - 2026)

TransMedics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 41.72% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 41.72% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 66.76% from the prior year.
• Current Deferred Revenue climbed to $2.9 million in Q1 2026 per TMDX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $3.3 million in Q3 2025 and bottomed at $226000.0 in Q3 2022.
• The 5-year median for Current Deferred Revenue is $1.7 million (2024), against an average of $1.5 million.
• Across the five-year window, Current Deferred Revenue surged 1063.27% in 2023 and dropped 16.93% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $241000.0 in 2022, then soared by 713.69% to $2.0 million in 2023, then fell by 11.17% to $1.7 million in 2024, then soared by 66.76% to $2.9 million in 2025, then increased by 1.38% to $2.9 million in 2026.
• Per Business Quant, the three latest TMDX Current Deferred Revenue figures stand at $2.9 million (Q1 2026), $2.9 million (Q4 2025), and $3.3 million (Q3 2025).